Market Overview:
The global next generation diabetes therapy and drug delivery market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of diabetes, technological advancements in drug delivery devices, and rising demand for minimally invasive therapies. Based on type, the next generation diabetes therapy and drug delivery market can be segmented into inhalable insulin, oral insulin, insulin patches, CGMs (continuous glucose monitoring systems), and artificial pancreas. Inhalable insulin is expected to witness the highest growth during the forecast period owing to its advantages such as ease of use and rapid absorption. Based on application, the next generation diabetes therapy and drug delivery market can be segmented into diagnostic/clinics settings; ICUs (intensive care units); home healthcare settings; and other applications including research institutes & pharmaceutical companies R&D centers).
Product Definition:
The term Next Generation Diabetes Therapy and Drug Delivery is used to describe an innovative approach to the treatment of diabetes. This approach involves the use of advanced drug delivery technologies and therapies that improve the way diabetes medications are delivered to patients. The aim of Next Generation Diabetes Therapy and Drug Delivery is to provide patients with more effective treatments that are easier to use and cause fewer side effects.
Inhalable Insulin:
Inhalable insulin is a drug delivery system that enables the controlled release of short acting insulin through the respiratory tract. The product was developed by Novo Nordisk as an alternative to conventional methods of delivering short acting insulin such as injections or oral tablets. inhalable insulin has been approved in Europe and Canada for treatment of diabetes mellitus type 1 and recently in 2014, it received FDA approval for usage in type 2 diabetes patients also.
Oral Insulin:
Oral insulin is a drug delivery system for the controlled administration of human insulin. It enables patients to administer human insulin as and when required by changing the formulation of oral dosage forms. The product has been approved in Europe, Canada, Australia, New Zealand and Japan for treatment of diabetes mellitus type 1 and 2 respectively. In addition, it has received approval from U.
Application Insights:
The drug delivery systems segment dominated the global next generation diabetes therapy and drug delivery market in 2017. This can be attributed to factors such as increasing R&D investments by companies for the development of innovative products. For instance, in January 2018, Novartis announced about entering into a partnership with Israel¢â‚¬â„¢s Teva Pharmaceuticals for the development of novel insulin Delivery Systems (ISS). The collaboration will focus on developing innovative products that will deliver insulin more effectively to patients.
In addition, growing awareness among people regarding their health is driving them towards adopting new technologies that are available in the market and this is also encouraging them to invest in these devices/therapies at an early stage before they reach commercialization phase.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of major players, high adoption rate of advanced therapies, and favorable reimbursement policies & regulatory approvals. The U.S., which is at the forefront of this region, has a well-established healthcare infrastructure that makes it an attractive destination for global diabetes therapy and drug delivery companies to invest in R&D activities for development of novel products as well as clinical trials for approval process.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income coupled with increasing awareness about new generation diabetes therapies & devices among patients across emerging countries such as China and India thereby boosting demand across this region during forecast years 2018 - 2030 (Global Next Generation Diabetes Therapy & Drug Delivery Market By Region). Moreover, growing medical tourism industry due to availability of effective treatment options at affordable costs will also boost demand further (Global NGTDD Market By Region).
Growth Factors:
- Increasing prevalence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is primarily due to the changing lifestyle and dietary habits of people across the world. According to a study by the International Diabetes Federation, there were 415 million people with diabetes in 2015 and this number is expected to reach 642 million by 2030. This growing population presents a huge opportunity for players in the Next Generation Diabetes Therapy and Drug Delivery market.
- Rising awareness about diabetes: There has been a significant increase in awareness about diabetes among people across all age groups in recent years. This has led to an increase in demand for better treatment options for managing this condition. Players operating in the Next Generation Diabetes Therapy and Drug Delivery market can capitalize on this trend by offering innovative products that meet the needs of patients effectively.
- Advances in technology: The field of medical technology is constantly evolving, with new advances being made every day that can be used to improve diagnosis and treatment options for various diseases, including diabetes mellitus type 2 (T2DM). Players operating in the Next Generation Diabetes Therapy and Drug Delivery market can benefit from these advances by incorporating them into their product offerings..
Scope Of The Report
Report Attributes
Report Details
Report Title
Next Generation Diabetes Therapy and Drug Delivery Market Research Report
By Type
Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas
By Application
Diagnostic/Clinics, ICUs, Home Healthcare
By Companies
Johnson & Johnson, Abbott Laboratories, Medtronic, Sanofi, Novo Nordisk, MannKind Corporation, Enteris BioPharma, Dexcom, Senseonics, Medtech, Synertech, Zosano Pharma, Relmada Therapeutics, Eli Lilly and Company, Transdermal Specialties
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
146
Number of Tables & Figures
103
Customization Available
Yes, the report can be customized as per your need.
Global Next Generation Diabetes Therapy and Drug Delivery Market Report Segments:
The global Next Generation Diabetes Therapy and Drug Delivery market is segmented on the basis of:
Types
Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Diagnostic/Clinics, ICUs, Home Healthcare
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Johnson & Johnson
- Abbott Laboratories
- Medtronic
- Sanofi
- Novo Nordisk
- MannKind Corporation
- Enteris BioPharma
- Dexcom
- Senseonics
- Medtech
- Synertech
- Zosano Pharma
- Relmada Therapeutics
- Eli Lilly and Company
- Transdermal Specialties
Highlights of The Next Generation Diabetes Therapy and Drug Delivery Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Inhalable Insulin
- Oral Insulin
- Insulin Patches
- CGM Systems
- Artificial Pancreas
- By Application:
- Diagnostic/Clinics
- ICUs
- Home Healthcare
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Next Generation Diabetes Therapy and Drug Delivery Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Next Generation Diabetes Therapy and Drug Delivery is a new approach to managing diabetes that uses drugs and devices to help people better control their blood sugar levels. This approach is based on the idea that itu2019s possible to improve blood sugar control by targeting specific areas of the body where insulin resistance occurs.
Some of the major players in the next generation diabetes therapy and drug delivery market are Johnson & Johnson, Abbott Laboratories, Medtronic, Sanofi, Novo Nordisk, MannKind Corporation, Enteris BioPharma, Dexcom, Senseonics, Medtech, Synertech, Zosano Pharma, Relmada Therapeutics, Eli Lilly and Company, Transdermal Specialties.
The next generation diabetes therapy and drug delivery market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Next Generation Diabetes Therapy and Drug Delivery Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Next Generation Diabetes Therapy and Drug Delivery Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Next Generation Diabetes Therapy and Drug Delivery Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Next Generation Diabetes Therapy and Drug Delivery Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Next Generation Diabetes Therapy and Drug Delivery Market Size & Forecast, 2018-2028
4.5.1 Next Generation Diabetes Therapy and Drug Delivery Market Size and Y-o-Y Growth
4.5.2 Next Generation Diabetes Therapy and Drug Delivery Market Absolute $ Opportunity
Chapter 5 Global Next Generation Diabetes Therapy and Drug Delivery Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Next Generation Diabetes Therapy and Drug Delivery Market Size Forecast by Type
5.2.1 Inhalable Insulin
5.2.2 Oral Insulin
5.2.3 Insulin Patches
5.2.4 CGM Systems
5.2.5 Artificial Pancreas
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Next Generation Diabetes Therapy and Drug Delivery Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Next Generation Diabetes Therapy and Drug Delivery Market Size Forecast by Applications
6.2.1 Diagnostic/Clinics
6.2.2 ICUs
6.2.3 Home Healthcare
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Next Generation Diabetes Therapy and Drug Delivery Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Next Generation Diabetes Therapy and Drug Delivery Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Next Generation Diabetes Therapy and Drug Delivery Analysis and Forecast
9.1 Introduction
9.2 North America Next Generation Diabetes Therapy and Drug Delivery Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Next Generation Diabetes Therapy and Drug Delivery Market Size Forecast by Type
9.6.1 Inhalable Insulin
9.6.2 Oral Insulin
9.6.3 Insulin Patches
9.6.4 CGM Systems
9.6.5 Artificial Pancreas
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Next Generation Diabetes Therapy and Drug Delivery Market Size Forecast by Applications
9.10.1 Diagnostic/Clinics
9.10.2 ICUs
9.10.3 Home Healthcare
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Next Generation Diabetes Therapy and Drug Delivery Analysis and Forecast
10.1 Introduction
10.2 Europe Next Generation Diabetes Therapy and Drug Delivery Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Next Generation Diabetes Therapy and Drug Delivery Market Size Forecast by Type
10.6.1 Inhalable Insulin
10.6.2 Oral Insulin
10.6.3 Insulin Patches
10.6.4 CGM Systems
10.6.5 Artificial Pancreas
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Next Generation Diabetes Therapy and Drug Delivery Market Size Forecast by Applications
10.10.1 Diagnostic/Clinics
10.10.2 ICUs
10.10.3 Home Healthcare
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Next Generation Diabetes Therapy and Drug Delivery Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Next Generation Diabetes Therapy and Drug Delivery Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Next Generation Diabetes Therapy and Drug Delivery Market Size Forecast by Type
11.6.1 Inhalable Insulin
11.6.2 Oral Insulin
11.6.3 Insulin Patches
11.6.4 CGM Systems
11.6.5 Artificial Pancreas
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Next Generation Diabetes Therapy and Drug Delivery Market Size Forecast by Applications
11.10.1 Diagnostic/Clinics
11.10.2 ICUs
11.10.3 Home Healthcare
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Next Generation Diabetes Therapy and Drug Delivery Analysis and Forecast
12.1 Introduction
12.2 Latin America Next Generation Diabetes Therapy and Drug Delivery Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Next Generation Diabetes Therapy and Drug Delivery Market Size Forecast by Type
12.6.1 Inhalable Insulin
12.6.2 Oral Insulin
12.6.3 Insulin Patches
12.6.4 CGM Systems
12.6.5 Artificial Pancreas
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Next Generation Diabetes Therapy and Drug Delivery Market Size Forecast by Applications
12.10.1 Diagnostic/Clinics
12.10.2 ICUs
12.10.3 Home Healthcare
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Next Generation Diabetes Therapy and Drug Delivery Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Next Generation Diabetes Therapy and Drug Delivery Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Next Generation Diabetes Therapy and Drug Delivery Market Size Forecast by Type
13.6.1 Inhalable Insulin
13.6.2 Oral Insulin
13.6.3 Insulin Patches
13.6.4 CGM Systems
13.6.5 Artificial Pancreas
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Next Generation Diabetes Therapy and Drug Delivery Market Size Forecast by Applications
13.10.1 Diagnostic/Clinics
13.10.2 ICUs
13.10.3 Home Healthcare
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Next Generation Diabetes Therapy and Drug Delivery Market: Competitive Dashboard
14.2 Global Next Generation Diabetes Therapy and Drug Delivery Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Johnson & Johnson
14.3.2 Abbott Laboratories
14.3.3 Medtronic
14.3.4 Sanofi
14.3.5 Novo Nordisk
14.3.6 MannKind Corporation
14.3.7 Enteris BioPharma
14.3.8 Dexcom
14.3.9 Senseonics
14.3.10 Medtech
14.3.11 Synertech
14.3.12 Zosano Pharma
14.3.13 Relmada Therapeutics
14.3.14 Eli Lilly and Company
14.3.15 Transdermal Specialties
